Structure-Based Design of 5‑Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)
收藏Figshare2019-07-12 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/Structure-Based_Design_of_5_Methylpyrimido_pyridone_Derivatives_as_New_Wild-Type_Sparing_Inhibitors_of_the_Epidermal_Growth_Factor_Receptor_Triple_Mutant_EGFR_sup_L858R_T790M_C797S_sup_/8986112
下载链接
链接失效反馈官方服务：
资源简介：
Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging “unmet clinical need” for non-small-cell lung cancer (NSCLC) patients. A series of 5-methylpyrimidopyridone derivatives were designed and synthesized as new selective EGFRL858R/T790M/C797S inhibitors. A representative compound, 8r-B, exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being a significantly less potent for EGFRWT (IC50 > 1.0 μM). Cocrystallographic structure determination and computational investigation were conducted to elucidate its target selectivity.
创建时间：
2019-07-12
